158 related articles for article (PubMed ID: 36660697)
1. Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients.
Sun Z; Wang F; Chen J; Liu X; Sun J; Sui Y; Zhang X; Shu Q
Ann Transl Med; 2022 Dec; 10(24):1365. PubMed ID: 36660697
[TBL] [Abstract][Full Text] [Related]
2. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
[TBL] [Abstract][Full Text] [Related]
3. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.
Archer R; Hock E; Hamilton J; Stevens J; Essat M; Poku E; Clowes M; Pandor A; Stevenson M
Health Technol Assess; 2018 Nov; 22(66):1-294. PubMed ID: 30501821
[TBL] [Abstract][Full Text] [Related]
4. A combination model to predict relapse and successful conventional DMARDs de-escalation in rheumatoid arthritis patients with sustained clinical remission.
Wang L; Geng Y; Han J; Sun X; Zhang Z
Clin Exp Rheumatol; 2019; 37(1):120-126. PubMed ID: 30148433
[TBL] [Abstract][Full Text] [Related]
5. Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.
Koga T; Okada A; Fukuda T; Hidaka T; Ishii T; Ueki Y; Kodera T; Nakashima M; Takahashi Y; Honda S; Horai Y; Watanabe R; Okuno H; Aramaki T; Izumiyama T; Takai O; Miyashita T; Sato S; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Origuchi T; Nakamura H; Aoyagi K; Eguchi K; Kawakami A;
PLoS One; 2017; 12(5):e0175281. PubMed ID: 28505163
[TBL] [Abstract][Full Text] [Related]
6. Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data.
Duong SQ; Crowson CS; Athreya A; Atkinson EJ; Davis JM; Warrington KJ; Matteson EL; Weinshilboum R; Wang L; Myasoedova E
Arthritis Res Ther; 2022 Jul; 24(1):162. PubMed ID: 35778714
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Hernández-Cruz B; Márquez-Saavedra E; Caliz-Caliz R; Navarro-Sarabia F
Arthritis Res Ther; 2016 Nov; 18(1):259. PubMed ID: 27821150
[TBL] [Abstract][Full Text] [Related]
8. Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial.
Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Christensen R; Ørnbjerg LM; Glinatsi D; Møller JM; Boesen M; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Larsen L; Jurik AG; Thomsen HS; Østergaard M
Scand J Rheumatol; 2022 Jul; 51(4):268-278. PubMed ID: 34474649
[TBL] [Abstract][Full Text] [Related]
9. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
Ramírez J; Narváez JA; Ruiz-Esquide V; Hernández-Gañán J; Cuervo A; Inciarte-Mundo J; Hernández MV; Sampayo-Cordero M; Pablos JL; Sanmartí R; Cañete JD
Semin Arthritis Rheum; 2017 Dec; 47(3):303-309. PubMed ID: 28549731
[TBL] [Abstract][Full Text] [Related]
10. Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study.
Cai YM; Li R; Ye H; He J; Sun XL; Jin JY; Liu JJ; Gan YZ; You XJ; Xu J; Shi LJ; Cheng G; Wang QW; Li ZG
Chin Med J (Engl); 2020 Jun; 133(12):1397-1403. PubMed ID: 32496302
[TBL] [Abstract][Full Text] [Related]
11. Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis.
Liu JJ; Li R; Gan YZ; Zhang RJ; Li J; Cai YM; Zhao JX; Liao H; Xu J; Shi LJ; Li J; Li SG; Sun XL; He J; Liu X; Ye H; Li ZG
Chin Med J (Engl); 2019 May; 132(9):1009-1014. PubMed ID: 30946065
[TBL] [Abstract][Full Text] [Related]
12. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
[TBL] [Abstract][Full Text] [Related]
14. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
[TBL] [Abstract][Full Text] [Related]
15. [Risk factor analysis on body mass rebound after laparoscopic sleeve gastrectomy and establishment of a nomogram prediction model].
Zhao J; Jiao YW; Qian J; Qian ZF; Yang HJ; Tang LM
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Oct; 25(10):913-920. PubMed ID: 36245117
[No Abstract] [Full Text] [Related]
16. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
[TBL] [Abstract][Full Text] [Related]
17. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
18. The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab.
Hirabayashi Y; Ishii T;
Clin Rheumatol; 2013 Jan; 32(1):123-7. PubMed ID: 23090655
[TBL] [Abstract][Full Text] [Related]
19. Inclusion of Synovial Tissue-Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment-Naive Rheumatoid Arthritis Patients.
Alivernini S; Tolusso B; Gessi M; Gigante MR; Mannocci A; Petricca L; Perniola S; Di Mario C; Bui L; Fedele AL; Capacci A; Bruno D; Peluso G; La Torre G; Federico F; Ferraccioli G; Gremese E
Arthritis Rheumatol; 2021 Sep; 73(9):1601-1613. PubMed ID: 33750008
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal monitor of Jun N-terminal kinase pathway associated phosphatase reflects clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs treatment in rheumatoid arthritis patients.
Song D; Zhu X; Wang F; Sun J
Inflammopharmacology; 2021 Aug; 29(4):1131-1138. PubMed ID: 34254203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
